Dr. Jakrapun Pupaibool, MD

Dr. Pupaibool practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Pupaibool's NPI, 1366690844, was assigned on September 8, 2008. Dr. Pupaibool holds Missouri license 2012034336.

Dr. Pupaibool's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Pupaibool's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Pupaibool is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Pupaibool to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pupaibool practices, 5 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Pupaibool's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Pupaibool's licenses on file in 2 states: Missouri and Minnesota.

CMS data shows 385 Medicare services from Dr. Pupaibool across 6 procedure codes in 2024, for 140 Medicare patients. Medicare paid $23,509 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 140 Medicare patients who saw Dr. Pupaibool in 2024. The largest group is 65 to 74, with 64 patients. 75% of them have high blood pressure, and 67% have arthritis. 21% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pupaibool's median patient age at 69, with 41% women.

In 2024, Dr. Pupaibool wrote 472 Medicare Part D claims for 248 patients. 92% of them were for generic drugs. CMS names the drug for 399 of them, across 11 drugs with 11 or more claims each, at $10,148 in total drug cost. In 2023, CMS named 407 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Pupaibool for performance year 2024, reported as part of a group. Dr. Pupaibool accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Pupaibool from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. DePuy Synthes Sales Inc. paid the most, $36.